Breastfeeding in patients with chronic myeloid leukaemia: case series with measurements of drug concentrations in maternal milk and review of literature
Breastfeeding in patients with chronic myeloid leukaemia (CML) who take tyrosine kinase inhibitors (TKIs) is not recommended but interruption of TKI treatment may cause the loss of remission. We observed the kinetics of the leukaemic clone in 3 women with CML in accordance with treatment interruptio...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2018-05-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | https://www.mjhid.org/index.php/mjhid/article/view/3331 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850033784988106752 |
|---|---|
| author | Ekaterina Chelysheva Sergey Aleshin Evgenia Polushkina Roman Shmakov Igor Shokhin Ghermes Chilov Anna Turkina |
| author_facet | Ekaterina Chelysheva Sergey Aleshin Evgenia Polushkina Roman Shmakov Igor Shokhin Ghermes Chilov Anna Turkina |
| author_sort | Ekaterina Chelysheva |
| collection | DOAJ |
| description | Breastfeeding in patients with chronic myeloid leukaemia (CML) who take tyrosine kinase inhibitors (TKIs) is not recommended but interruption of TKI treatment may cause the loss of remission. We observed the kinetics of the leukaemic clone in 3 women with CML in accordance with treatment interruptions for pregnancy and breastfeeding. The concentrations of nilotinib and imatinib in maternal milk were measured when the breastfeeding period was over. Nilotinib transfer into human breast milk was demonstrated for the first time and had a maximum concentration (Cmax) 129 ng/ml after 4 hours of the drug intake at a dose of 400 mg. The Cmax of imatinib in maternal milk ranged from 420 to 1411 ng/ml after 4-8 hours of the drug intake at a dose of 400-600 mg. Breastfeeding without TKI treatment may be safe with molecular monitoring, but preferably in those patients with CML who have durable deep molecular response. |
| format | Article |
| id | doaj-art-3a1a8666e2af4988bf60adae9bab80b4 |
| institution | DOAJ |
| issn | 2035-3006 |
| language | English |
| publishDate | 2018-05-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Mediterranean Journal of Hematology and Infectious Diseases |
| spelling | doaj-art-3a1a8666e2af4988bf60adae9bab80b42025-08-20T02:58:04ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062018-05-01101e2018027e201802710.4084/mjhid.2018.0271754Breastfeeding in patients with chronic myeloid leukaemia: case series with measurements of drug concentrations in maternal milk and review of literatureEkaterina Chelysheva0Sergey Aleshin1Evgenia Polushkina2Roman Shmakov3Igor Shokhin4Ghermes Chilov5Anna Turkina6National Research Center for HematologyCenter of Pharmaceutical Analytics LtdFSBI National Research Center of Obstetrics, Gynecology and Perinatology of the Healthcare Ministry named after V.I. KulakovFSBI National Research Center of Obstetrics, Gynecology and Perinatology of the Healthcare Ministry named after V.I. KulakovCenter of Pharmaceutical Analytics LtdFSBI N.D. Zelinsky Institute of Organic Chemistry of Russian Academy of SciencesNational Research Center for HematologyBreastfeeding in patients with chronic myeloid leukaemia (CML) who take tyrosine kinase inhibitors (TKIs) is not recommended but interruption of TKI treatment may cause the loss of remission. We observed the kinetics of the leukaemic clone in 3 women with CML in accordance with treatment interruptions for pregnancy and breastfeeding. The concentrations of nilotinib and imatinib in maternal milk were measured when the breastfeeding period was over. Nilotinib transfer into human breast milk was demonstrated for the first time and had a maximum concentration (Cmax) 129 ng/ml after 4 hours of the drug intake at a dose of 400 mg. The Cmax of imatinib in maternal milk ranged from 420 to 1411 ng/ml after 4-8 hours of the drug intake at a dose of 400-600 mg. Breastfeeding without TKI treatment may be safe with molecular monitoring, but preferably in those patients with CML who have durable deep molecular response.https://www.mjhid.org/index.php/mjhid/article/view/3331chronic myeloid leukaemia, pregnancy, breastfeeding, milk, breast milk, imatinib, nilotinib, dasatinib, molecular response |
| spellingShingle | Ekaterina Chelysheva Sergey Aleshin Evgenia Polushkina Roman Shmakov Igor Shokhin Ghermes Chilov Anna Turkina Breastfeeding in patients with chronic myeloid leukaemia: case series with measurements of drug concentrations in maternal milk and review of literature Mediterranean Journal of Hematology and Infectious Diseases chronic myeloid leukaemia, pregnancy, breastfeeding, milk, breast milk, imatinib, nilotinib, dasatinib, molecular response |
| title | Breastfeeding in patients with chronic myeloid leukaemia: case series with measurements of drug concentrations in maternal milk and review of literature |
| title_full | Breastfeeding in patients with chronic myeloid leukaemia: case series with measurements of drug concentrations in maternal milk and review of literature |
| title_fullStr | Breastfeeding in patients with chronic myeloid leukaemia: case series with measurements of drug concentrations in maternal milk and review of literature |
| title_full_unstemmed | Breastfeeding in patients with chronic myeloid leukaemia: case series with measurements of drug concentrations in maternal milk and review of literature |
| title_short | Breastfeeding in patients with chronic myeloid leukaemia: case series with measurements of drug concentrations in maternal milk and review of literature |
| title_sort | breastfeeding in patients with chronic myeloid leukaemia case series with measurements of drug concentrations in maternal milk and review of literature |
| topic | chronic myeloid leukaemia, pregnancy, breastfeeding, milk, breast milk, imatinib, nilotinib, dasatinib, molecular response |
| url | https://www.mjhid.org/index.php/mjhid/article/view/3331 |
| work_keys_str_mv | AT ekaterinachelysheva breastfeedinginpatientswithchronicmyeloidleukaemiacaseserieswithmeasurementsofdrugconcentrationsinmaternalmilkandreviewofliterature AT sergeyaleshin breastfeedinginpatientswithchronicmyeloidleukaemiacaseserieswithmeasurementsofdrugconcentrationsinmaternalmilkandreviewofliterature AT evgeniapolushkina breastfeedinginpatientswithchronicmyeloidleukaemiacaseserieswithmeasurementsofdrugconcentrationsinmaternalmilkandreviewofliterature AT romanshmakov breastfeedinginpatientswithchronicmyeloidleukaemiacaseserieswithmeasurementsofdrugconcentrationsinmaternalmilkandreviewofliterature AT igorshokhin breastfeedinginpatientswithchronicmyeloidleukaemiacaseserieswithmeasurementsofdrugconcentrationsinmaternalmilkandreviewofliterature AT ghermeschilov breastfeedinginpatientswithchronicmyeloidleukaemiacaseserieswithmeasurementsofdrugconcentrationsinmaternalmilkandreviewofliterature AT annaturkina breastfeedinginpatientswithchronicmyeloidleukaemiacaseserieswithmeasurementsofdrugconcentrationsinmaternalmilkandreviewofliterature |